Nektar Therapeutics (NKTR) Gross Margin: 2010-2025
Historic Gross Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to 12.66%.
- Nektar Therapeutics' Gross Margin fell 4169.00% to 12.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.74%, marking a year-over-year decrease of 2701.00%. This contributed to the annual value of 57.28% for FY2024, which is 161.00% down from last year.
- Per Nektar Therapeutics' latest filing, its Gross Margin stood at 12.66% for Q3 2025, which was up 66.29% from 7.62% recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Gross Margin ranged from a high of 78.95% in Q3 2022 and a low of -65.01% during Q1 2025.
- In the last 3 years, Nektar Therapeutics' Gross Margin had a median value of 52.22% in 2024 and averaged 38.00%.
- In the last 5 years, Nektar Therapeutics' Gross Margin skyrocketed by 1,473bps in 2024 and then tumbled by 11,323bps in 2025.
- Nektar Therapeutics' Gross Margin (Quarterly) stood at 75.36% in 2021, then slumped by 366bps to 71.70% in 2022, then tumbled by 1,592bps to 55.78% in 2023, then soared by 1,473bps to 70.51% in 2024, then tumbled by 4,169bps to 12.66% in 2025.
- Its Gross Margin was 12.66% in Q3 2025, compared to 7.62% in Q2 2025 and -65.01% in Q1 2025.